Cardiogen
Ala-Glu-Asp-Arg / AEDR peptide
Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, designed as a bioregulator peptide specific to cardiac tissue. It is theorized to normalize gene expression in cardiomyocytes by penetrating cell nuclei and interacting with DNA regulatory sequences. Research applications focus on cardiac tissue repair, prevention of age-related myocardial deterioration, and post-ischemic cardioprotection.
Mécanisme d'action
Synthetic tetrapeptide bioregulator that targets cardiac tissue. Promotes cardiomyocyte differentiation, enhances cardiac stem cell activity, and may improve myocardial function by modulating gene expression in heart tissue. Part of the Khavinson bioregulator class.
Protocoles de recherche
Pour des fins de recherche uniquement. Pas de conseil médical.
Research protocols (Khavinson method) use 10-20mg orally or sublingually daily for 10-30 day cycles. Sublingual preferred. Cycles repeated every 3-6 months.
Notes de recherche
Clinical Research Status
Cardiogen has been investigated in clinical studies conducted primarily in Russia, with reports of improved cardiac function markers in elderly patients with age-related cardiovascular deterioration. Studies have examined its use both as a standalone intervention and in combination with other bioregulator peptides as part of comprehensive anti-aging protocols. It is available as a supplement in Russia but has not been evaluated by Western regulatory agencies or subjected to large-scale randomized controlled trials meeting international standards.
Key Published Findings
Research demonstrates that Cardiogen can stimulate proliferation and differentiation of cardiac stem cells in vitro, potentially contributing to myocardial regeneration. Animal studies show reduced infarct size and improved left ventricular function when administered following experimental myocardial ischemia. Gene expression analysis indicates upregulation of cardioprotective factors including heat shock proteins and anti-apoptotic genes in cardiomyocyte cultures exposed to Cardiogen.
Safety Profile
Available literature reports no adverse effects from Cardiogen administration at recommended doses, consistent with the general safety profile of ultrashort bioregulator peptides. Its constituent amino acids (alanine, glutamic acid, aspartic acid, arginine) are all naturally occurring and rapidly metabolized through normal physiological pathways. No contraindications have been formally established, though patients with active cardiac conditions should not use investigational peptides as substitutes for established medical treatments.
Comparison to Related Compounds
Cardiogen is tissue-specific to cardiac muscle, while the related Khavinson peptide Vessels (Lys-Glu-Asp-Trp) targets vascular endothelium, and Thymalin addresses immune function. Unlike BPC-157, which provides general tissue healing through angiogenesis and growth factor modulation, Cardiogen is theorized to work through direct gene regulatory mechanisms specific to cardiomyocytes. Compared to pharmaceutical cardioprotective agents like trimetazidine, Cardiogen represents a fundamentally different approach through peptide bioregulation rather than metabolic modulation.
Community Observations
Users in longevity-focused communities often incorporate Cardiogen as part of broader Khavinson peptide stacks targeting multiple organ systems simultaneously. Reported benefits are generally subtle and difficult to verify without echocardiographic or biomarker monitoring, making subjective assessment challenging. The peptide is typically used in 10-30 day cycles several times per year, following protocols established in Russian gerontological practice.
Moitié de vie
~15-30 minutes
Réconstitution
N/A (typically oral/sublingual capsule)
Conservation
Lyophilisé
Room temperature. Protect from moisture.
Réconstitué
N/A (oral form)
Statut légal aux États-Unis
Autres noms connus
Questions fréquentes
Qu'est-ce que Cardiogen ?
Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, designed as a bioregulator peptide specific to cardiac tissue. It is theorized to normalize gene expression in cardiomyocytes by penetrating cell nuclei and interacting with DNA regulatory sequences. Research applications focus on cardiac tissue repair, prevention of age-related myocardial deterioration, and post-ischemic cardioprotection.
Comment agit Cardiogen ?
Synthetic tetrapeptide bioregulator that targets cardiac tissue. Promotes cardiomyocyte differentiation, enhances cardiac stem cell activity, and may improve myocardial function by modulating gene expression in heart tissue. Part of the Khavinson bioregulator class.
Quel est le statut réglementaire de Cardiogen aux États-Unis ?
Research chemical (not FDA-approved)
Quelle est la demi-vie de Cardiogen ?
~15-30 minutes
Sous quels autres noms Cardiogen est-il connu ?
Ala-Glu-Asp-Arg, AEDR peptide
Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.
Lire la déclaration complète